Kudo-Saito, et al Supplementary Figure 1 Leukocytes Lymphocytes Debris Dead cells Human PBMCs.

Slides:

Advertisements

Similar presentations

Fig. S1 HUVECs HDFNs HUVECs HDFNs Transwell CM Relative total length ** * control 200ng/ml400ng/ml TIMP-1 100ng/ml * ** GFP WT Mutant TIMP-1 TIMP-1 **

Advertisements

Clancy-Thompson et al., Supplemental Figure 1 A B C Supplemental Figure 1: Mice were given intravenous B16 injection on day 0. A) After bearing tumors.

Suppl. Figure 1 A B Suppl. Figure 1. Relative (A) miR-21 and (B) miR-224 expression levels in HCC tumors in different stages (I,II,III,IV) assessed by.

Supplementary Figure 1 Supplementary Figure 1. Representative micrographs of migration and invasion assays. miR-452 or si-WWP1 transfectants inhibited.

Supplementary information Figure S1 Parental Mock ANXA1-V5 GAPDH MCF7-EV MCF7-V5 4 5 ANXA1 ANXA1-V5 Tubulin MCF7-parental MCF7-EV MCF7-V A B C ANXA1.

Figure 2. Effects of RUNX1 and PU. 1 siRNAs on CCR3 reporter activity

Figure S1. qPCR analysis of the EMT markers ZEB2 and SNAI1 in Syndecan-1 and control siRNA transfected MDA-MB-231 and MCF-7 cells reveals no significant.

Foxp3 induction dependent on cell cycle progression in vitro.

Supplementary FigureS4 (Feduska et al.)

a b SUM149PT Motility Invasion C V C V

Immunologic pathomechanism of Hodgkin's lymphoma

FOXP3 regulates cAMP production by regulating miR‐142‐3p and AC9.

SDHB deficiency promotes TGFβ-mediated invasion and metastasis of colorectal cancer through transcriptional repression complex SNAIL1-SMAD3/4 Haiyu Wang,

Anti–4-1BB/PD-1 combination enriched CD8+ T cells in TILs

Immunologic pathomechanism of Hodgkin's lymphoma

Treg's Alter Ego: An Accessory in Tumor Killing

Marissa V. Powers, Paul A. Clarke, Paul Workman Cancer Cell

Cell signaling and cancer

Tailor-Made Renal Cell Carcinoma Vaccines

Induction of antigen-specific regulatory T lymphocytes by human dendritic cells expressing the glucocorticoid-induced leucine zipper by Haifa Hamdi, Véronique.

Days after cell inoculation Days after cell inoculation

Days after cell inoculation Days after cell inoculation

Figure 3 Differentiation and functional control of T-cell subsets

Marissa V. Powers, Paul A. Clarke, Paul Workman Cancer Cell

The inhibition of PI3K and Akt in human T cells selectively inhibits the proliferation of human Tregs compared with Tconvs in a dose-dependent manner.

Supplementary Figure 1 Non-migrating cells Migrating cells

Mock ICSBP Snail Slug Twist β-actin Suppl. Fig. 1.

Molecular Therapy - Nucleic Acids

TIGIT-CD155 Interactions in Melanoma: A Novel Co-Inhibitory Pathway with Potential for Clinical Intervention Karsten Mahnke, Alexander H. Enk Journal.

PDGFRβ is dispensable for EGFRvIII-driven GBM growth but is required for the optimal growth of EGFR-inhibited tumors. PDGFRβ is dispensable for EGFRvIII-driven.

a c b d e * * －＋ Supplementary Figure 0.2 HCF (ALP / G3PDH) 0.1 SK-1

A B Supplementary figure S5 ** ** ** ** ** **

* * Supplementary figure S4 A B C D

Supplementary figure S2

Consequences of reducing SF3B2 expression.

Induction of T-Cell Responses against Cutaneous T-Cell Lymphomas Ex Vivo by Autologous Dendritic Cells Transfected with Amplified Tumor mRNA Xiao Ni,

ABIN-1 inhibits IL-17–dependent NF-κB activation.

HeLa COS-7 Supplementary Figure S1 Coelho et al (2014) MM pSPL3 MM

Roth et al, Supplementary Figure 1

(apoptotic + necrotic)

The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity

Jürgen C. Becker, David Schrama Journal of Investigative Dermatology

Chie Kudo-Saito, Hiromi Shirako, Tadashi Takeuchi, Yutaka Kawakami

Autocrine IL-6 Signaling: A Key Event in Tumorigenesis?

Figure 3 Underlying mechanisms of TREG cells in atherosclerosis

PD-1–PD-L1 axis is highly expressed and is not IFNγ-dependent in a subcutaneous murine model of PDA. A, experimental design for establishment of subcutaneous.

C A B * * * * HCC1954 HCC1569 Supplementary-Figure S5 Tumor cells sc.

PTK6 downregulation suppresses SNAIL and increases E-cadherin expression. PTK6 downregulation suppresses SNAIL and increases E-cadherin expression. A,

Supplemental Figure 1 Cell proliferation (% of mock)

Releasing the Brakes on Cancer Immunotherapy

Reduced tumor growth in CCR5-deficient mice is associated with perturbed killing ability of Treg cells. Reduced tumor growth in CCR5-deficient mice is.

SiRNA silencing of CDH3, CLDN1, KRT23, and MMP7 (A–D) in adenoma and CRC cell lines significantly reduces cell proliferation. siRNA silencing of CDH3,

Model of the accumulation of Treg cells in human tumors.

Induction of cytotoxic activity in humanized SCC3 tumor-bearing mice treated with anti-PD-1 antibody. Induction of cytotoxic activity in humanized SCC3.

Canonical but not adaptive NK-cell function is suppressed by Tregs.

Combination of miR-520d-3p and EphA2 siRNA treatment shows enhanced EphA2 inhibition and antitumor efficiency in vitro. Combination of miR-520d-3p and.

Rumwald Leo G Lecaros, Leaf Huang, Tsai-Chia Lee, Yih-Chih Hsu

DAC treatment alters immune cell composition and enhances cytokine production in the peritoneal lavage. DAC treatment alters immune cell composition and.

Adhesion to fibronectin protects Mcl-1 knockdown cells from apoptosis.

Knockdown of ERBB3, NRG1, or ERBB2 in H358-TwistER cells reduces basal PI3K–AKT signaling and ablates serum-independent proliferation before EMT. A and.

Anti-CD40 activates TAMs and recruits inflammatory monocytes.

Effects of ASGR2 knockdown on the phenotypes of MKN1 cells.

HOXA11-AS acts as a ceRNA for miR-1297.

Effect of MIF siRNA on the production of MMP-13 induced by LPA

IL2Cx alone or in combination with anti–CTLA-4 increases the CD8/Treg ratio in the tumor. IL2Cx alone or in combination with anti–CTLA-4 increases the.

Recruitment of CD8+, CD4+, and Foxp3+ cells into oral lesions in response to anti–PD-1 treatment. Recruitment of CD8+, CD4+, and Foxp3+ cells into oral.

Cell counts of immune infiltrate and expression of galectin-1 and galectin-3 in the short-, medium-, and long-term survival cohorts. Cell counts of immune.

Wnt5A and ROR2 contribute to intrinsic resistance to BRAF inhibitors.

Stable IL-10: A New Therapeutic that Promotes Tumor Immunity

**** *** * **** **** *** Shahriary et al.- Supplementary Figure 4 (a)

Presentation transcript:

Kudo-Saito, et al Supplementary Figure 1 Leukocytes Lymphocytes Debris Dead cells Human PBMCs

Panc1-mock D6-snail+ D10-snail+ F3-snail+ F5-snail+ Snail E-cadherin Fibronectin Morphology Proliferation InvasionAdhesion Mock D6 D10 F3 F5 NC Snail Slug Twist E-cadherin Fibronectin MMP2 Collagen IV GAPDH Transfectants Absorbance (570nm) No. of cells (a) (b) (c) Normalization Snail E-cadherin Fibronectin Mock D6 D10 F3 F Mock D6 D10 F3 F5 Mock D6 D10 F3 F5 Mock D6 D10 F3 F5 Kudo-Saito, et al Supplementary Figure 2 Absorbance ( nm)

Kudo-Saito, et al Supplementary Figure 3 Snail transfectants CCL2 (a) CCL2SnailF10-mockControl Foxp3 in CD4 + cells Snail CCL2 LCN2 GAPDH H6 + siRNA ng/ml Mock E9 H6 Mock E9 H LCN2 Mock E9 H ng/ml Control Snail CCL2 Mock Control Snail CCL2 Mock H6 + siRNA (c) CCL2LCN2 H6 + siRNA Snail CCL2 LCN2 GAPDH H6 + siRNA Control Snail CCL2 #1 CCL2 #2 Mock (b)

ControlsiRNA-snailsiRNA-CCL CD4 I-A(b) B16-F10 tumors 64% (466) 62% (630) 60% (816) Foxp3 in CD4 + cells 79% (2058) 78% (1984) 81% (535) Gp70 tetramer in CD8 + cells CD11c (b) CD8 (a) Tumor volume (mm 3 ) Control Snail CCL2 B16-F10 + siRNA (c) IFN-γ (pg/ml) Control Snail CCL2 B16-F10 + siRNA Kudo-Saito, et al Supplementary Figure 4

Kudo-Saito, et al Supplementary Figure 5 ControlsiRNA-snailsiRNA-CCL CD4 I-A(b) F10-mock H6-snail + tumors CD (1430) (1180) (1150) (816) Foxp3 in CD4 + cells (289) (1521) (2231) (535) Gp70 tetramer in CD8 + cells CD11c

Kudo-Saito, et al Supplementary Figure 6 Snail + cancer cell undergoing EMT CCL2 release Recruitment of CD4 low FOXP3 + CCR2 + Treg Induction of CD4 + FOXP3 + Treg Induction of CD11c + HLA-DR low DCreg Inhibition of CTL induction LCN2 release (autocrine) Enhancement of cancer invasion